Regulation of STATs by polycystin-1 and their role in polycystic kidney disease

References

• Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60:321 - 37; http://dx.doi.org/10.1146/annurev.med.60.101707.125712; PMID: 18947299
   PubMed Web of Science ®Google Scholar
• Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17:118 - 30; http://dx.doi.org/10.1053/j.ackd.2010.01.002; PMID: 20219615
   PubMed Web of Science ®Google Scholar
• Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011; 79:502 - 11; http://dx.doi.org/10.1038/ki.2010.457; PMID: 21085109
   PubMed Web of Science ®Google Scholar
• Hofherr A, Köttgen M. TRPP channels and polycystins. Adv Exp Med Biol 2011; 704:287 - 313; http://dx.doi.org/10.1007/978-94-007-0265-3_16; PMID: 21290302
   PubMed Web of Science ®Google Scholar
• Zhou J. Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 2009; 71:83 - 113; http://dx.doi.org/10.1146/annurev.physiol.70.113006.100621; PMID: 19572811
   PubMed Web of Science ®Google Scholar
• Berbari NF, O’Connor AK, Haycraft CJ, Yoder BK. The primary cilium as a complex signaling center. Curr Biol 2009; 19:R526 - 35; http://dx.doi.org/10.1016/j.cub.2009.05.025; PMID: 19602418
   PubMed Web of Science ®Google Scholar
• Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011; 364:1533 - 43; http://dx.doi.org/10.1056/NEJMra1010172; PMID: 21506742
   PubMed Web of Science ®Google Scholar
• Weimbs T. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 2007; 293:F1423 - 32; http://dx.doi.org/10.1152/ajprenal.00275.2007; PMID: 17715262
   PubMedGoogle Scholar
• Weimbs T. Third-hit signaling in renal cyst formation. J Am Soc Nephrol 2011; 22:793 - 5; http://dx.doi.org/10.1681/ASN.2011030284; PMID: 21493772
   PubMed Web of Science ®Google Scholar
• Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010; 363:879 - 81; http://dx.doi.org/10.1056/NEJMe1006925; PMID: 20581393
   PubMed Web of Science ®Google Scholar
• Weimbs T, Talbot JJ. STAT3 Signaling in Polycystic Kidney Disease. Drug Discov Today Dis Mech 2013; In press http://dx.doi.org/10.1016/j.ddmec.2013.03.001
   Google Scholar
• Levy DE, Darnell JE Jr.. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651 - 62; http://dx.doi.org/10.1038/nrm909; PMID: 12209125
   PubMed Web of Science ®Google Scholar
• Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002; 2:381 - 92; http://dx.doi.org/10.2174/1566524023362456; PMID: 12108949
   PubMedGoogle Scholar
• Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004; 279:41679 - 85; http://dx.doi.org/10.1074/jbc.M406413200; PMID: 15284232
   PubMed Web of Science ®Google Scholar
• Stepkowski SM, Chen W, Ross JA, Nagy ZS, Kirken RA. STAT3: an important regulator of multiple cytokine functions. Transplantation 2008; 85:1372 - 7; http://dx.doi.org/10.1097/TP.0b013e3181739d25; PMID: 18497672
   PubMed Web of Science ®Google Scholar
• Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. JAK-STAT 2012; 1:65 - 72; http://dx.doi.org/10.4161/jkst.20045
   PubMedGoogle Scholar
• Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem 2012; 55:6645 - 68; http://dx.doi.org/10.1021/jm300207s; PMID: 22650325
   PubMed Web of Science ®Google Scholar
• Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005; 65:5828 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-05-0317; PMID: 15994959
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70:2445 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-09-2468; PMID: 20215512
   PubMed Web of Science ®Google Scholar
• Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012; 30:916 - 26; http://dx.doi.org/10.1007/s10637-011-9645-1; PMID: 21340507
   PubMed Web of Science ®Google Scholar
• Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007; 104:7391 - 6; http://dx.doi.org/10.1073/pnas.0609757104; PMID: 17463090
   PubMed Web of Science ®Google Scholar
• Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11:595 - 6; http://dx.doi.org/10.1038/nm0605-595; PMID: 15937466
   PubMed Web of Science ®Google Scholar
• Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011; 18:4012 - 8; http://dx.doi.org/10.2174/092986711796957284; PMID: 21824090
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011; 18:2359 - 75; http://dx.doi.org/10.2174/092986711795843218; PMID: 21568920
   PubMed Web of Science ®Google Scholar
• Page BDG, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat 2011; 21:65 - 83; http://dx.doi.org/10.1517/13543776.2011.539205; PMID: 21114420
   PubMed Web of Science ®Google Scholar
• Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380:630 - 3; http://dx.doi.org/10.1038/380630a0; PMID: 8602264
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4:313 - 9; http://dx.doi.org/10.1016/S1074-7613(00)80439-2; PMID: 8624821
   PubMed Web of Science ®Google Scholar
• Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006; 17:173 - 88; http://dx.doi.org/10.1016/j.cytogfr.2006.01.004; PMID: 16540365
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451 - 83; http://dx.doi.org/10.1146/annurev.immunol.021908.132532; PMID: 19105661
   PubMed Web of Science ®Google Scholar
• Elo LL, Järvenpää H, Tuomela S, Raghav S, Ahlfors H, Laurila K, et al. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 2010; 32:852 - 62; http://dx.doi.org/10.1016/j.immuni.2010.06.011; PMID: 20620947
   PubMed Web of Science ®Google Scholar
• Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, Ramos HL, et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 2010; 32:840 - 51; http://dx.doi.org/10.1016/j.immuni.2010.06.003; PMID: 20620946
   PubMed Web of Science ®Google Scholar
• Urban JF Jr., Schopf L, Morris SC, Orekhova T, Madden KB, Betts CJ, et al. Stat6 signaling promotes protective immunity against Trichinella spiralis through a mast cell- and T cell-dependent mechanism. J Immunol 2000; 164:2046 - 52; PMID: 10657657
   PubMed Web of Science ®Google Scholar
• Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202:175 - 90; http://dx.doi.org/10.1111/j.0105-2896.2004.00215.x; PMID: 15546393
   PubMed Web of Science ®Google Scholar
• Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM, et al. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol 1995; 15:3336 - 43; PMID: 7760829
   PubMed Web of Science ®Google Scholar
• Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Kubo M, LaRochelle WJ, et al. Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem 2000; 275:29331 - 7; http://dx.doi.org/10.1074/jbc.M910290199; PMID: 10882748
   PubMed Web of Science ®Google Scholar
• Gupta S, Jiang M, Pernis AB. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol 1999; 163:3834 - 41; PMID: 10490982
   PubMed Web of Science ®Google Scholar
• Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, Heim MH. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem 1998; 254:514 - 9; http://dx.doi.org/10.1046/j.1432-1327.1998.2540514.x; PMID: 9688261
   PubMedGoogle Scholar
• Hua K, Deng J, Harp JB. Interleukin-4 inhibits platelet-derived growth factor-induced preadipocyte proliferation. Cytokine 2004; 25:61 - 7; http://dx.doi.org/10.1016/j.cyto.2003.09.008; PMID: 14693161
   PubMed Web of Science ®Google Scholar
• Chen H, Sun H, You F, Sun W, Zhou X, Chen L, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 2011; 147:436 - 46; http://dx.doi.org/10.1016/j.cell.2011.09.022; PMID: 22000020
   PubMed Web of Science ®Google Scholar
• Denkers EY, Bzik DJ, Fox BA, Butcher BA. An inside job: hacking into Janus kinase/signal transducer and activator of transcription signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect Immun 2012; 80:476 - 82; http://dx.doi.org/10.1128/IAI.05974-11; PMID: 22104110
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Y, Sharma N, Tarasova NI, Timofeeva OA, Winkler-Pickett RT, et al. STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal 2010; 22:1717 - 26; http://dx.doi.org/10.1016/j.cellsig.2010.06.012; PMID: 20624457
   PubMed Web of Science ®Google Scholar
• Talbot JJ, Shillingford JM, Vasanth S, Doerr N, Mukherjee S, Kinter MT, et al. Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A 2011; 108:7985 - 90; http://dx.doi.org/10.1073/pnas.1103816108; PMID: 21518865
   PubMed Web of Science ®Google Scholar
• Kim M, O’Brien LE, Kwon SH, Mostov KE. STAT1 is required for redifferentiation during Madin-Darby canine kidney tubulogenesis. Mol Biol Cell 2010; 21:3926 - 33; http://dx.doi.org/10.1091/mbc.E10-02-0112; PMID: 20861313
   PubMed Web of Science ®Google Scholar
• Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443 - 50; http://dx.doi.org/10.1016/S0092-8674(00)81289-1; PMID: 8608598
   PubMed Web of Science ®Google Scholar
• Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84:431 - 42; http://dx.doi.org/10.1016/S0092-8674(00)81288-X; PMID: 8608597
   PubMed Web of Science ®Google Scholar
• Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc Natl Acad Sci U S A 2002; 99:943 - 8; http://dx.doi.org/10.1073/pnas.022628499; PMID: 11782537
   PubMed Web of Science ®Google Scholar
• Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007; 13:1490 - 5; http://dx.doi.org/10.1038/nm1675; PMID: 17965720
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Andò M, Tamagnone L, Bardelli A, Michieli P, Battistini C, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998; 391:285 - 8; http://dx.doi.org/10.1038/34657; PMID: 9440692
   PubMed Web of Science ®Google Scholar
• Santos OF, Barros EJ, Yang XM, Matsumoto K, Nakamura T, Park M, et al. Involvement of hepatocyte growth factor in kidney development. Dev Biol 1994; 163:525 - 9; http://dx.doi.org/10.1006/dbio.1994.1169; PMID: 8200486
   PubMed Web of Science ®Google Scholar
• Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19:1106 - 15; http://dx.doi.org/10.1681/ASN.2007070744; PMID: 18337485
   PubMed Web of Science ®Google Scholar
• Wang J, Ouyang C, Chen X, Fu B, Lu Y, Hong Q. STAT3 inhibits apoptosis of human renal tubular epithelial cells induced by ATP depletion/recovery. Nephron Exp Nephrol 2008; 108:e11 - 8; http://dx.doi.org/10.1159/000112557; PMID: 18097150
   PubMedGoogle Scholar
• Arany I, Megyesi JK, Nelkin BD, Safirstein RL. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006; 70:669 - 74; http://dx.doi.org/10.1038/sj.ki.5001604; PMID: 16788692
   PubMed Web of Science ®Google Scholar
• Arany I, Reed DK, Grifoni SC, Chandrashekar K, Booz GW, Juncos LA. A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. Am J Physiol Renal Physiol 2012; 302:F722 - 9; http://dx.doi.org/10.1152/ajprenal.00338.2011; PMID: 22169004
   PubMed Web of Science ®Google Scholar
• Ogata K, Shimamura Y, Hamada K, Hisa M, Bun M, Okada N, et al. Upregulation of HNF-1β during experimental acute kidney injury plays a crucial role in renal tubule regeneration. Am J Physiol Renal Physiol 2012; 303:F689 - 99; http://dx.doi.org/10.1152/ajprenal.00086.2012; PMID: 22759397
   PubMedGoogle Scholar
• Yang N, Luo M, Li R, Huang Y, Zhang R, Wu Q, et al. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rat. Nephrol Dial Transplant 2008; 23:91 - 100; http://dx.doi.org/10.1093/ndt/gfm509; PMID: 17670769
   PubMed Web of Science ®Google Scholar
• Kuratsune M, Masaki T, Hirai T, Kiribayashi K, Yokoyama Y, Arakawa T, et al. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton) 2007; 12:565 - 71; http://dx.doi.org/10.1111/j.1440-1797.2007.00881.x; PMID: 17995582
   PubMed Web of Science ®Google Scholar
• Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 2010; 78:257 - 68; http://dx.doi.org/10.1038/ki.2010.154; PMID: 20520592
   PubMed Web of Science ®Google Scholar
• Li R, Yang N, Zhang L, Huang Y, Zhang R, Wang F, et al. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol 2007; 27:580 - 9; http://dx.doi.org/10.1159/000108102; PMID: 17823504
   PubMed Web of Science ®Google Scholar
• Olsan EE, Mukherjee S, Wulkersdorfer B, Shillingford JM, Giovannone AJ, Todorov G, et al. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A 2011; 108:18067 - 72; http://dx.doi.org/10.1073/pnas.1111966108; PMID: 22025716
   PubMed Web of Science ®Google Scholar
• Yokota N, Burne-Taney M, Racusen L, Rabb H. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2003; 285:F319 - 25; PMID: 12709397
   PubMedGoogle Scholar
• Yukawa K, Kishino M, Goda M, Liang XM, Kimura A, Tanaka T, et al. STAT6 deficiency inhibits tubulointerstitial fibrosis in obstructive nephropathy. Int J Mol Med 2005; 15:225 - 30; PMID: 15647835
   PubMed Web of Science ®Google Scholar
• Summers SA, Phoon RK, Odobasic D, Dewage L, Kitching AR, Holdsworth SR. Signal transducer and activation of transcription 6 (STAT6) regulates T helper type 1 (Th1) and Th17 nephritogenic immunity in experimental crescentic glomerulonephritis. Clin Exp Immunol 2011; 166:227 - 34; http://dx.doi.org/10.1111/j.1365-2249.2011.04437.x; PMID: 21985369
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang Z, Jiang L, Ye F, Wang J, Wu P. Elevated interleukin-13 in patients with active lupus nephritis. Chin Med J (Engl) 2001; 114:1022 - 5; PMID: 11677758
   PubMed Web of Science ®Google Scholar
• Lakkis FG, Cruet EN. Cloning of rat interleukin-13 (IL-13) cDNA and analysis of IL-13 gene expression in experimental glomerulonephritis. Biochem Biophys Res Commun 1993; 197:612 - 8; http://dx.doi.org/10.1006/bbrc.1993.2523; PMID: 7916615
   PubMed Web of Science ®Google Scholar
• Sandovici M, Henning RH, van Goor H, Helfrich W, de Zeeuw D, Deelman LE. Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 2008; 73:1364 - 73; http://dx.doi.org/10.1038/ki.2008.18; PMID: 18354382
   PubMed Web of Science ®Google Scholar
• Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002; 109:157 - 68; http://dx.doi.org/10.1016/S0092-8674(02)00716-X; PMID: 12007403
   PubMed Web of Science ®Google Scholar
• Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 2006; 10:57 - 69; http://dx.doi.org/10.1016/j.devcel.2005.12.005; PMID: 16399078
   PubMed Web of Science ®Google Scholar
• Chauvet V, Tian X, Husson H, Grimm DH, Wang T, Hiesberger T, et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 2004; 114:1433 - 43; PMID: 15545994
   PubMed Web of Science ®Google Scholar
• Li X, Luo Y, Starremans PG, McNamara CA, Pei Y, Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol 2005; 7:1202 - 12; http://dx.doi.org/10.1038/ncb1326; PMID: 16311606
   PubMed Web of Science ®Google Scholar
• Felekkis KN, Koupepidou P, Kastanos E, Witzgall R, Bai CX, Li L, et al. Mutant polycystin-2 induces proliferation in primary rat tubular epithelial cells in a STAT-1/p21-independent fashion accompanied instead by alterations in expression of p57KIP2 and Cdk2. BMC Nephrol 2008; 9:10; http://dx.doi.org/10.1186/1471-2369-9-10; PMID: 18721488
   PubMed Web of Science ®Google Scholar
• Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011; 300:F1193 - 202; http://dx.doi.org/10.1152/ajprenal.00419.2010; PMID: 21345977
   PubMed Web of Science ®Google Scholar
• Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011; 20:4143 - 54; http://dx.doi.org/10.1093/hmg/ddr338; PMID: 21821671
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269:199 - 225; http://dx.doi.org/10.1016/j.canlet.2008.03.009; PMID: 18479807
   PubMed Web of Science ®Google Scholar
• Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, et al. Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 2011; 654:92 - 9; http://dx.doi.org/10.1016/j.ejphar.2010.12.008; PMID: 21187084
   PubMed Web of Science ®Google Scholar
• Harris PC. What is the role of somatic mutation in autosomal dominant polycystic kidney disease?. J Am Soc Nephrol 2010; 21:1073 - 6; http://dx.doi.org/10.1681/ASN.2010030328; PMID: 20488953
   PubMed Web of Science ®Google Scholar
• Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 2004; 13:3069 - 77; http://dx.doi.org/10.1093/hmg/ddh336; PMID: 15496422
   PubMed Web of Science ®Google Scholar
• Ward CJ, Turley H, Ong AC, Comley M, Biddolph S, Chetty R, et al. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc Natl Acad Sci U S A 1996; 93:1524 - 8; http://dx.doi.org/10.1073/pnas.93.4.1524; PMID: 8643665
   PubMed Web of Science ®Google Scholar
• Lanoix J, D’Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 1996; 13:1153 - 60; PMID: 8808689
   PubMed Web of Science ®Google Scholar
• Prasad S, McDaid JP, Tam FW, Haylor JL, Ong AC. Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury. Am J Pathol 2009; 175:1493 - 503; http://dx.doi.org/10.2353/ajpath.2009.090227; PMID: 19729489
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr., Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res 2006; 326:671 - 85; http://dx.doi.org/10.1007/s00441-006-0226-0; PMID: 16767405
   PubMed Web of Science ®Google Scholar
• Horie S, Higashihara E, Nutahara K, Mikami Y, Okubo A, Kano M, et al. Mediation of renal cyst formation by hepatocyte growth factor. Lancet 1994; 344:789 - 91; http://dx.doi.org/10.1016/S0140-6736(94)92344-2; PMID: 7916076
   PubMed Web of Science ®Google Scholar
• Takayama H, LaRochelle WJ, Sabnis SG, Otsuka T, Merlino G. Renal tubular hyperplasia, polycystic disease, and glomerulosclerosis in transgenic mice overexpressing hepatocyte growth factor/scatter factor. Lab Invest 1997; 77:131 - 8; PMID: 9274855
   PubMed Web of Science ®Google Scholar
• Torres VE, Sweeney WE Jr., Wang X, Qian Q, Harris PC, Frost P, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003; 64:1573 - 9; http://dx.doi.org/10.1046/j.1523-1755.2003.00256.x; PMID: 14531789
   PubMed Web of Science ®Google Scholar
• Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J, et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 2010; 120:3617 - 28; http://dx.doi.org/10.1172/JCI41531; PMID: 20852388
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr., von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19:1331 - 41; http://dx.doi.org/10.1681/ASN.2007060665; PMID: 18385429
   PubMed Web of Science ®Google Scholar
• Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22:1809 - 14; http://dx.doi.org/10.1681/ASN.2011010084; PMID: 21921140
   PubMed Web of Science ®Google Scholar
• Chatterjee PK, Al-Abed Y, Sherry B, Metz CN. Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol 2009; 297:C1294 - 306; http://dx.doi.org/10.1152/ajpcell.00160.2009; PMID: 19741199
   PubMed Web of Science ®Google Scholar
• Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10:47 - 50; http://dx.doi.org/10.1016/S0960-9822(99)00268-7; PMID: 10660304
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006; 103:5466 - 71; http://dx.doi.org/10.1073/pnas.0509694103; PMID: 16567633
   PubMed Web of Science ®Google Scholar
• Calvet JP. MEK inhibition holds promise for polycystic kidney disease. J Am Soc Nephrol 2006; 17:1498 - 500; http://dx.doi.org/10.1681/ASN.2006040353; PMID: 16687624
   PubMed Web of Science ®Google Scholar
• Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17:6508 - 16; PMID: 9343414
   PubMed Web of Science ®Google Scholar
• Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009; 323:793 - 7; http://dx.doi.org/10.1126/science.1164551; PMID: 19131594
   PubMed Web of Science ®Google Scholar
• Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008; 18:443 - 51; http://dx.doi.org/10.1038/cr.2008.41; PMID: 18364677
   PubMed Web of Science ®Google Scholar
• Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65:939 - 47; PMID: 15705894
   PubMed Web of Science ®Google Scholar
• Zhou J, Ouyang X, Schoeb TR, Bolisetty S, Cui X, Mrug S, et al. Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J Am Soc Nephrol 2012; 23:1161 - 71; http://dx.doi.org/10.1681/ASN.2011050442; PMID: 22518005
   PubMed Web of Science ®Google Scholar
• Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 2008; 6:1099 - 105; http://dx.doi.org/10.1158/1541-7786.MCR-07-2177; PMID: 18644974
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170:830 - 42; http://dx.doi.org/10.2353/ajpath.2007.060455; PMID: 17322369
   PubMed Web of Science ®Google Scholar
• Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50:861 - 7; http://dx.doi.org/10.1016/0006-2952(95)00255-X; PMID: 7575649
   PubMed Web of Science ®Google Scholar
• Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270:22467 - 72; http://dx.doi.org/10.1074/jbc.270.38.22467; PMID: 7673235
   PubMed Web of Science ®Google Scholar
• Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160:1581 - 8; PMID: 9469413
   PubMed Web of Science ®Google Scholar
• Norman J. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta 2011; 1812:1327 - 36; http://dx.doi.org/10.1016/j.bbadis.2011.06.012; PMID: 21745567
   PubMed Web of Science ®Google Scholar
• Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69:213 - 7; http://dx.doi.org/10.1038/sj.ki.5000054; PMID: 16408108
   PubMed Web of Science ®Google Scholar
• Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, ten Dijke P, et al. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 2010; 222:21 - 31; PMID: 20549648
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12:99 - 106; http://dx.doi.org/10.1038/nm1332; PMID: 16327802
   PubMed Web of Science ®Google Scholar
• Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, et al. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut 2013; 62:63 - 72; http://dx.doi.org/10.1136/gutjnl-2011-300498; PMID: 22287592
   PubMed Web of Science ®Google Scholar
• Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004; 173:4020 - 9; PMID: 15356151
   PubMed Web of Science ®Google Scholar
• Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118:98 - 104; http://dx.doi.org/10.1016/j.jaci.2006.02.046; PMID: 16815144
   PubMed Web of Science ®Google Scholar
• Wallace DP, Quante MT, Reif GA, Nivens E, Ahmed F, Hempson SJ, et al. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am J Physiol Renal Physiol 2008; 295:F1463 - 71; http://dx.doi.org/10.1152/ajprenal.90266.2008; PMID: 18753297
   PubMed Web of Science ®Google Scholar
• Iwata Y, Boström EA, Menke J, Rabacal WA, Morel L, Wada T, et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol 2012; 188:4568 - 80; http://dx.doi.org/10.4049/jimmunol.1102154; PMID: 22467656
   PubMed Web of Science ®Google Scholar
• Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 2007; 179:3926 - 36; PMID: 17785830
   PubMed Web of Science ®Google Scholar